226
Palm C, Netzereab S, Hallbrink M (2006) Quantitatively determined uptake of cell-penetrating
peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects.
Peptides 27(7):1710–1716. https://doi.org/10.1016/j.peptides.2006.01.006
Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M et al (2018) Nusinersen
in type 1 SMA infants, children and young adults: preliminary results on motor function.
Neuromuscul Disord 28(7):582–585. https://doi.org/10.1016/j.nmd.2018.05.010
Pavlova N, Penchovsky R (2019) Genome-wide bioinformatics analysis of FMN, SAM-I, glmS,
TPP, lysine, purine, cobalamin, and SAH riboswitches for their applications as allosteric antibacterial drug targets in human pathogenic bacteria. Expert opinion on therapeutic targets
23(7):631–643. https://doi.org/10.1080/14728222.2019.1618274
Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M (2016) Bacteriophage
therapy: a regulatory perspective. J Antimicrob Chemother 71(8):2071–2074. https://doi.
org/10.1093/jac/dkw083
Pena C, Pujol M, Ricart A, Ardanuy C, Ayats J, Linares J et al (1997) Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in
the intensive care unit. J Hosp Infect 35(1):9–16
Penchovsky R, Traykovska M (2015) Designing drugs that overcome antibacterial resistance:
where do we stand and what should we do? Expert Opin Drug Discov 10(6):631–650. https://
doi.org/10.1517/17460441.2015.1048219
Pfalzgraff A, Brandenburg K, Weindl G (2018) Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. Front Pharmacol 9:281. https://doi.org/10.3389/
fphar.2018.00281
Reiner Z (2018) Triglyceride-rich lipoproteins and novel targets for anti-atherosclerotic therapy.
Korean Circ J 48(12):1097–1119. https://doi.org/10.4070/kcj.2018.0343
Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9–21. https://doi.org/10.1038/nrneurol.2017.148
Rodriguez Plaza JG, Morales-Nava R, Diener C, Schreiber G, Gonzalez ZD, Lara Ortiz MT et al
(2014) Cell penetrating peptides and cationic antibacterial peptides: two sides of the same coin.
J Biol Chem 289(21):14448–14457. https://doi.org/10.1074/jbc.M113.515023
Rodriguez L, Martinez B, Zhou Y, Rodriguez A, Donovan DM, Garcia P (2011) Lytic activity of
the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage
vB_SauS-phiIPLA88. BMC Microbiol 11:138. https://doi.org/10.1186/1471-2180-11-138
Rodriguez-Mozaz S, Chamorro S, Marti E, Huerta B, Gros M, Sanchez-Melsio A et al (2015)
Occurrence of antibiotics and antibiotic resistance genes in hospital and urban wastewaters
and their impact on the receiving river. Water Res 69:234–242. https://doi.org/10.1016/j.
watres.2014.11.021
Runti G, Benincasa M, Giuffrida G, Devescovi G, Venturi V, Gennaro R, Scocchi M (2017)
The mechanism of killing by the proline-rich peptide Bac7(1-35) against clinical strains of
Pseudomonas aeruginosa differs from that against other Gram-negative bacteria. Antimicrob
Agents Chemother 61(4). https://doi.org/10.1128/AAC.01660-16
Scocchi M, Tossi A, Gennaro R (2011) Proline-rich antimicrobial peptides: converging to a nonlytic mechanism of action. Cell Mol Life Sci 68(13):2317–2330. https://doi.org/10.1007/
s00018-011-0721-7
Seil M, Nagant C, Dehaye JP, Vandenbranden M, Lensink MF (2010) Spotlight on human LL-37,
an immunomodulatory peptide with promising cell-penetrating properties. Pharmaceuticals
3(11):3435–3460. https://doi.org/10.3390/ph3113435
Selgelid MJ (2007) Ethics and drug resistance. Bioethics 21(4):218–229. https://doi.
org/10.1111/j.1467-8519.2006.00542.x
Septimus EJ (2018) Antimicrobial resistance: an antimicrobial/diagnostic stewardship and infection prevention approach. Med Clin North Am 102(5):819–829. https://doi.org/10.1016/j.
mcna.2018.04.005
Seth PP, Tanowitz M, Bennett CF (2019) Selective tissue targeting of synthetic nucleic acid drugs.
J Clin Invest 129(3):915–925. https://doi.org/10.1172/JCI125228
A. Valsamatzi-Panagiotou et al.
Palm C, Netzereab S, Hallbrink M (2006) Quantitatively determined uptake of cell-penetrating
peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects.
Peptides 27(7):1710–1716. https://doi.org/10.1016/j.peptides.2006.01.006
Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M et al (2018) Nusinersen
in type 1 SMA infants, children and young adults: preliminary results on motor function.
Neuromuscul Disord 28(7):582–585. https://doi.org/10.1016/j.nmd.2018.05.010
Pavlova N, Penchovsky R (2019) Genome-wide bioinformatics analysis of FMN, SAM-I, glmS,
TPP, lysine, purine, cobalamin, and SAH riboswitches for their applications as allosteric antibacterial drug targets in human pathogenic bacteria. Expert opinion on therapeutic targets
23(7):631–643. https://doi.org/10.1080/14728222.2019.1618274
Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M (2016) Bacteriophage
therapy: a regulatory perspective. J Antimicrob Chemother 71(8):2071–2074. https://doi.
org/10.1093/jac/dkw083
Pena C, Pujol M, Ricart A, Ardanuy C, Ayats J, Linares J et al (1997) Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in
the intensive care unit. J Hosp Infect 35(1):9–16
Penchovsky R, Traykovska M (2015) Designing drugs that overcome antibacterial resistance:
where do we stand and what should we do? Expert Opin Drug Discov 10(6):631–650. https://
doi.org/10.1517/17460441.2015.1048219
Pfalzgraff A, Brandenburg K, Weindl G (2018) Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. Front Pharmacol 9:281. https://doi.org/10.3389/
fphar.2018.00281
Reiner Z (2018) Triglyceride-rich lipoproteins and novel targets for anti-atherosclerotic therapy.
Korean Circ J 48(12):1097–1119. https://doi.org/10.4070/kcj.2018.0343
Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9–21. https://doi.org/10.1038/nrneurol.2017.148
Rodriguez Plaza JG, Morales-Nava R, Diener C, Schreiber G, Gonzalez ZD, Lara Ortiz MT et al
(2014) Cell penetrating peptides and cationic antibacterial peptides: two sides of the same coin.
J Biol Chem 289(21):14448–14457. https://doi.org/10.1074/jbc.M113.515023
Rodriguez L, Martinez B, Zhou Y, Rodriguez A, Donovan DM, Garcia P (2011) Lytic activity of
the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage
vB_SauS-phiIPLA88. BMC Microbiol 11:138. https://doi.org/10.1186/1471-2180-11-138
Rodriguez-Mozaz S, Chamorro S, Marti E, Huerta B, Gros M, Sanchez-Melsio A et al (2015)
Occurrence of antibiotics and antibiotic resistance genes in hospital and urban wastewaters
and their impact on the receiving river. Water Res 69:234–242. https://doi.org/10.1016/j.
watres.2014.11.021
Runti G, Benincasa M, Giuffrida G, Devescovi G, Venturi V, Gennaro R, Scocchi M (2017)
The mechanism of killing by the proline-rich peptide Bac7(1-35) against clinical strains of
Pseudomonas aeruginosa differs from that against other Gram-negative bacteria. Antimicrob
Agents Chemother 61(4). https://doi.org/10.1128/AAC.01660-16
Scocchi M, Tossi A, Gennaro R (2011) Proline-rich antimicrobial peptides: converging to a nonlytic mechanism of action. Cell Mol Life Sci 68(13):2317–2330. https://doi.org/10.1007/
s00018-011-0721-7
Seil M, Nagant C, Dehaye JP, Vandenbranden M, Lensink MF (2010) Spotlight on human LL-37,
an immunomodulatory peptide with promising cell-penetrating properties. Pharmaceuticals
3(11):3435–3460. https://doi.org/10.3390/ph3113435
Selgelid MJ (2007) Ethics and drug resistance. Bioethics 21(4):218–229. https://doi.
org/10.1111/j.1467-8519.2006.00542.x
Septimus EJ (2018) Antimicrobial resistance: an antimicrobial/diagnostic stewardship and infection prevention approach. Med Clin North Am 102(5):819–829. https://doi.org/10.1016/j.
mcna.2018.04.005
Seth PP, Tanowitz M, Bennett CF (2019) Selective tissue targeting of synthetic nucleic acid drugs.
J Clin Invest 129(3):915–925. https://doi.org/10.1172/JCI125228
A. Valsamatzi-Panagiotou et al.